BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Daclizumab high-yield process: Phase IIb data

Top-line data from the double-blind, international Phase IIb SELECT trial in 600 patients showed that once-monthly 150 and 300 mg subcutaneous daclizumab each met the primary endpoint of ARR compared to placebo. Specifically, low- and high-dose daclizumab reduced ARR by 54% and 50%, respectively, vs. placebo at 1 year (p<0.0001 and p=0.0002, respectively). Compared to placebo, low- and high-dose daclizumab also met the secondary endpoints of significantly reducing the cumulative number of new gadolinium-enhancing lesions between weeks 8-24 (69% and 78%, respectively); the number of new or newly-enlarging...

Read the full 419 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >